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Abstract
: In articles reporting randomized controlled trials, professionalBackground
medical writing support is associated with increased adherence to
Consolidated Standards of Reporting Trials (CONSORT). We set out to
determine whether professional medical writing support was also associated
with improved adherence to CONSORT for Abstracts.
: Using data from a previously published cross-sectional study of 463Methods
articles reporting randomized controlled trials published between 2011 and
2014 in five top medical journals, we determined the association between
professional medical writing support and CONSORT for Abstracts items using
a Wilcoxon rank-sum test.
: The mean proportion of adherence to CONSORT for Abstracts itemsResults
reported was similar with and without professional medical writing support
(64.3% vs 66.5%, respectively; p=0.30). Professional medical writing support
was associated with lower adherence to reporting study setting (relative risk
[RR]; 0.40; 95% confidence interval [CI], 0.23–0.70), and higher adherence to
disclosing harms/side effects (RR 2.04; 95% CI, 1.37–3.03) and funding source
(RR 1.75; 95% CI, 1.18–2.60).
: Although professional medical writing support was notConclusions
associated with increased overall adherence to CONSORT for Abstracts,
important aspects were improved with professional medical writing support,
including reporting of adverse events and funding source. This study identifies
areas to consider for improvement.
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Introduction
Prior studies demonstrate low levels of adherence to Consolidated 
Standards of Reporting Trials (CONSORT) guidelines1,2, as well 
as CONSORT for Abstracts3,4 in reporting randomized control-
led trials (RCTs). Professional medical writing support, correctly 
acknowledged, is endorsed by Good Publication Practice (GPP3)5, 
and its prevalence increased between 2001/2002 and 2009/2010, 
with a reported doubling to nearly 35% of industry-sponsored 
studies6. Professional medical writing support is associated with 
increased adherence to CONSORT in articles reporting RCTs; 
in a sample of open-access journals, the number of articles that 
completely reported ≥50% of the studied CONSORT items was 
significantly higher with professional medical writing support 
(39%) than without professional medical writing support (21%; 
p<0.05)7,8.
The purpose of this study was to determine whether profes-
sional medical writing support was also associated with improved 
adherence to CONSORT for Abstracts by analyzing a published 
dataset from five high-impact general medical journals with 
overall variable and incomplete adherence9.
Methods
We examined data from a published cross-sectional study of 463 
articles reporting RCTs9. The RCTs were published between 2011 
and 2014 in five top medical journals: The New England Journal of 
Medicine, Annals of Internal Medicine, The Lancet, The BMJ, and 
JAMA. We determined the association between professional medi-
cal writing support and the reporting of CONSORT for Abstracts 
items10 (Table 1) using a Wilcoxon rank-sum test. One author (CS), 
who was blinded to the CONSORT for Abstracts scores using 
de-identified original dataset outputs, identified articles as being 
prepared with professional medical writing support using auto-
mated searching of the full text article followed by manual review 
if they acknowledged the involvement of one of the following: 
medical writer, medical writing, writing services, writing assist-
ance, editorial assistance, or editorial support. The context of 
these terms was also examined.
Mean proportions of CONSORT for Abstract adherence with and 
without professional medical writing support was compared using 
a Wilcoxon rank-sum test, and then tested with additional effect of 
variable journal adherence using an analysis of variance (ANOVA). 
The relative risk (RR) and 95% confidence interval (CI) for each 
item’s adherence with and without professional medical writing 
support were calculated using the command “oddsratio” in the 
R package fmsb 0.5.211. All statistical analyses were performed in 
R 3.2.212. 
Results
From the original published dataset of 463 abstracts from 
RCTs reported in five journals, acknowledged professional 
medical writing support was observed in 66 articles (14.3%). 
Two articles identified in the automated search were excluded on 
manual review, one of which stated13, “there was no writing 
assistance from anyone who is not listed as an author,” and the 
other14, “the Writing committee drafted the report… without edito-
rial assistance.” The mean proportion of CONSORT for Abstracts 
items reported in articles with (n=66) and without (n=397) pro-
fessional medical writing support was 64.3% versus 66.5%, 
respectively; p=0.3044 (Wilcoxon rank-sum test). This difference 
remained nonsignificant when journal variation in CONSORT for 
Abstracts adherence was considered (ANOVA, p=0.1347). Over-
all, reporting of the individual CONSORT for Abstracts items was 
similar with and without professional medical writing support (RR 
0.97; 95% CI, 0.88–1.07) (Figure 1). However, a lower rate of 
reporting the study setting (item 4) was observed in articles with 
professional medical writing support (RR 0.40; 95% CI, 
0.23–0.70). Conversely, professional medical writing support was 
associated with higher adherence to reporting both harms and 
side effects (item 16) (RR 2.04; 95% CI, 1.37–3.03) and source of 
funding (item 19) (RR 1.75; 95% CI, 1.18–2.60).
Dataset 1. Dataset for reporting of CONSORT for Abstracts items 
in articles with and without acknowledged professional medical 
writing support
http://dx.doi.org/10.5256/f1000research.12268.d172437
Dataset used per Hays et al.9 with the addition of column C for this 
post hoc analysis by professional medical writing support (yes: 1; 
no: 0).
Discussion
Although professional medical writing support was not associ-
ated with increased overall adherence to CONSORT for Abstracts, 
important aspects were improved with professional medical writing 
support, including reporting of adverse events and funding source. 
These data confirm prior evidence showing that professional medi-
cal writing support is associated with improved safety reporting15, 
and serve to support the important role of professional medical 
writers in promoting adherence to Medical Publishing Insights & 
Practices recommendations to improve adverse event reporting in 
clinical trial publications16. Reporting of funding source was also 
improved with professional medical writing support, most likely 
reflecting the emphasis placed on transparency about funding by 
GPP3 guidelines5,17. In articles with professional medical writing 
support, we observed 100% adherence for other important CON-
SORT for Abstract items, including reporting of the clinical tri-
als registration number (item 18), vital for transparency and study 
tracking, which has recently been automated using technology such 
as the TrialsTracker18.
In this post hoc analysis, there was substantial risk of false posi-
tives given that separate confidence intervals were computed 
for 19 different CONSORT items. However, the p value for 
      Amendments from Version 1
We have revised our publication to further clarify the methodology 
and robustness of the observed differences in CONSORT for 
Abstracts adherence with and without professional medical 
writing support, and in the context of the published literature. 
See referee reports
REVISED
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Table 1. CONSORT for Abstracts checklist items10, with descriptors by Hays et al.9 as used for this post hoc analysis.
CONSORT for Abstracts items
Abstract evaluation checklist Yes No
Title 
      1.    Do the authors state explicitly in the title that the participants were randomly assigned to their comparison groups?
Trial design 
      2.     Is the type of randomized controlled trial described (e.g. parallel group, cluster randomized, crossover, factorial,  
superiority, noninferiority, or some other combination of these)?
Methods 
Participants 
      3.     Is there a clear description of the eligibility criteria for trial participants (e.g. inclusion and/or exclusion criteria)?  
Can the reader reasonably describe the study population and assess the generalizability of the trial?
      4.     Is there a clear description of the setting of the participants studied (i.e. primary/secondary/tertiary care center, 
government health clinic, community clinic; level of care provided at study site)? This does not have to mention 
geographic setting (i.e. country).
Intervention 
      5.     Are essential features of the experimental and comparison interventions described, including details about the 
interventions (e.g. dose, route of administration, duration of administration, surgical procedure, or manufacturer of 
inserted device)? The abstract must give details about the intervention to help the reader quickly assess the validity 
of the study.
Objective 
      6.     Is there a clear statement of the specific objective or hypothesis addressed in the trial? Either a clear statement is 
made or it is not.
Outcome 
      7.     Do the authors explicitly state the primary or main outcome for the trial and when it was assessed (e.g. the time 
frame over which it was measured)?
Randomization 
      8.     Do the authors clearly describe the method for random sequence generation in assigning participants to 
interventions?
      9.    Do the authors clearly describe the method of allocation concealment?
Blinding 
      10.    Is the study “blinded” or “masked” to group assignment?
      11.     Does the abstract specify who was “blinded” or “masked” (e.g. participants, caregivers, those assessing outcomes, 
data analysts)?
Results 
      12.    Is the number of participants randomized to each group stated?
      13.     Is the number of participants analyzed for each group stated?
      14.    Is the primary outcome result for each group stated?
      15.    Is there an estimated effect size and precision (i.e. are confidence intervals given)?
      16.     Is there an explicit statement of harms or side effects, or an explicit statement of their absence? Harms and side 
effects do not have to be specifically labeled as such. Abstracts can satisfy this criterion by stating specific 
outcomes that are not the primary objective of the study and could reasonably be considered a harm or side effect 
of the intervention or treatment. This is typically stated in the last sentence of the results.
Conclusions 
      17.    Is the interpretation of the trial clearly stated?
Registration 
      18.    Is the trial registration number and trial register stated?
Funding 
      19.    Is the source of funding for the trial stated?
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Figure 1. Reporting of CONSORT for Abstracts items in articles with and without acknowledged professional medical writing support. 
CONSORT, Consolidated Standards of Reporting Trials; PMWS, professional medical writing support. Significant associations are shaded.
setting (item 4) was 0.0010, for harms or side effects (item 16) 
was 0.0004, and for source of funding (item 19) was 0.0055; the 
first two survive a Bonferroni correction, which would conserva-
tively demand that p<0.0026, and all three pass the less stringent 
Benjamini-Hochberg procedure. Nevertheless, we were disap-
pointed to see that professional medical writing support was not 
associated with improvements in reporting of other CONSORT 
for Abstract items, including specification in the title of the design 
of the study (item 2) and that it was randomized (item 1), and 
reporting of the numbers randomized and analyzed (items 12 
and 13). Indeed, professional medical writing support was actu-
ally associated with worse reporting of one item, study setting 
(item 4) which may be explained by a lack of prioritization by pro-
fessional medical writers within the constraints of abstract word 
count limitations. These areas represent clear areas in which pro-
fessional medical writers can help further improve the reporting 
of clinical trials in the abstracts of journal articles. The relatively 
small number of studies with professional medical writing support 
is this dataset (n=66) did not allow for further exploration of 
these data (e.g. type of funding, trial phase, institutions where 
performed). It would be of interest to determine if similar trends 
are observed in separate studies of CONSORT for Abstracts 
adherence.
Although this was a post-hoc analysis, it has the advantage 
that CONSORT for Abstracts adherence was assessed before 
our study question was posed. Additionally, the presence of 
professional medical writing support was assigned by an asses-
sor who was blinded to the CONSORT for Abstracts score. 
However, in the original study, inter-rater agreement for scoring 
was 84%, which is suboptimal9. Furthermore, the original dataset 
was limited to a sample of high-impact journals, and so may not 
be generalizable to the biomedical literature as a whole. Indeed, 
in this dataset of high-impact journals, adherence to CONSORT 
for Abstracts is likely to have been influenced by the journal’s 
in-house scientific editing; consequently, the impact of professional 
medical writing support on adherence to CONSORT for Abstracts 
may be greater in journals without professional in-house edit-
ing. These data were potentially confounded by funding source; 
because professional medical writing support is typically restricted 
to industry-funded studies, it is possible that the review processes 
followed by industry19, rather than professional medical writ-
ing support per se, caused the improvements in reporting that we 
observed. However, in industry-funded articles, professional medi-
cal writing support was associated with a greater than two-fold 
increase in ≥50% adherence to CONSORT items studied com-
pared with industry-funded articles prepared without this support 
(38% vs 18%, p<0.05)7,8. In addition, industry funding alone had 
no impact on the quality of CONSORT reporting in the absence 
of professional medical writing support7,8. Nevertheless, it can 
be difficult to correctly ascribe the role of the funder from the details 
provided in manuscripts as, for example, investigator-led studies 
typically undergo a different review process to those conducted 
with full industry support20. Finally, although Good Publication 
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Practice guidelines (GPP3) encourage transparency of profes-
sional medical writing support21, it remains possible that it was not 
consistently acknowledged in the studied dataset. In a systematic 
review of the medical literature, the prevalence of ghostwriting 
was found to be approximately 5%22. Any unacknowledged pro-
fessional medical writing support would tend towards the null 
hypothesis enhancing the confidence in the observed statistical 
differences.
In summary, although professional medical writing support was 
not associated with increased overall adherence to CONSORT 
for Abstracts, important aspects were improved with professional 
medical writing support, including reporting of adverse events 
and funding source. Ensuring adherence to reporting guidelines 
is a complex task, so we believe that there is a role for reporting 
professionals such as professional medical writers to work 
with authors and journals, to provide training, writing and 
reviewing, and thereby improve the quality of reporting of clinical 
trials.
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    Jackie M. Marchington
Caudex, Oxford, UK
This is a subanalysis of a previous study detailing the completeness of clinical study reporting in abstracts
according to the CONSORT for abstracts checklist. The original publication was restricted to a sample of
clinical trial publications in 5 high-ranking general medical journals. This subanalysis investigated
differences in adherence to CONSORT for abstracts between papers with or without acknowledged
professional medical writing support.
With respect to the co-authors' previous study, citation of the full paper (ref 8) is sufficient. Citing the
poster of the same study is not necessary (ref 7).
Regarding the methods, it is not clear how automated searching would have identified the presence of
professional medical writing support. In this reviewer's experience, that has always required retrieval of
the full text article. If the automated search was performed on each full text article, I think it would be
clearer to state this.
In the discussion, the authors point out funding source as a potential confounder of their results. It would
perhaps be of interest to examine industry-funded studies written up without acknowledged professional
medical writing support as an additional comparator group to determine whether industry funding was
driving differences in CONSORT adherence.
I also have a niggling concern that although GPP3 encourages transparency around the involvement of
non-author contributors such as professional medical writers in industry-funded publications, there may
be papers in this cohort that used unacknowledged medical writers, papers where a professional writer
was included as an author, so not acknowledged as such, or non-industry funded papers where the
authors used institutional editorial/writing resource that is not acknowledged. Perhaps the authors could
comment on this potential limitation in the discussion.
Although this is a fairly straightforward subanalysis of a previous study, I think it makes an important
contribution to the evidence base about the role of professional medical writers, even though the findings
are neutral in terms of adherence to CONSORT for abstracts.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
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 Are the conclusions drawn adequately supported by the results?
Yes
 I work for a company that provides professional medical writing services toCompeting Interests:
pharmaceutical and biotechnology clients. I am active in national and international not-for-profit
associations that encourage ethical medical writing practices.
Referee Expertise: Professional medical writing, publication ethics
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Author Response 11 Sep 2017
, PAREXEL, USAIra Mills
We thank   for her insight and providing suggestions to improve our paper.Jackie Marchington
Although Good Publication Practice guidelines (GPP3) encourage transparency of professional
medical writing support, it remains possible that professional medical writing support was not
consistently acknowledged in the studied dataset, and cited evidence in the literature of its
prevalence. Any unacknowledged professional medical writing support would tend towards the null
hypothesis enhancing the confidence in the observed statistical differences.
As noted by the referee, we have pointed out funding source as a potential confounder of the
results and provided discussion as to some of these considerations. The relatively low number of
articles with acknowledged professional medical writing support did not allow us to conduct an
analysis of professional medical writing support with and without industry support with any
statistical validity.
In our paper to support cited information, we have listed both reference 7 (full publication) and
reference 8 (corresponding abstract for a prior congress presentation) as the abstract reported p
values not found in the full publication. We have swapped the order of the references to have the
full publication cited first. 
 No competing interests were disclosed.Competing Interests:
 17 August 2017Referee Report
doi:10.5256/f1000research.13282.r25066
   Ana Marušić
Department of Research in Biomedicine and Health, University of Split School of Medicine, Split, Croatia
This study presents secondary analysis of a study of adherence to CONSORT reporting guidelines for
Abstracts. While the original study (Hays et al, 2016) looked at this adherence in a sample of abstracts
from several high-profile medical journals, this study performed a subgroup analysis, looking at whether
the mention of professional writing assistance was associated with the score for different items on the
reporting checklist. The study is thus quite methodologically biased, and it is not clear whether the
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 reporting checklist. The study is thus quite methodologically biased, and it is not clear whether the
observed differences are real, or random. For example, the finding that the acknowledgment of
professional writing assistance decreases the frequency of adequately reporting the setting of the study is
difficult to explain. The potential randomness of the significant findings should be addressed in the
Discussion section.
Making a publication out of the original publication by looking at a single characteristic does not really
warrant the publication of the submitted manuscript. It would be preferable if other characteristics were
explored in relation to reporting completeness in abstracts, such as the type of funding, phase of the trial,
institutions where trials were performed.
The manuscript is well written and structured, and there are no major comments or suggestions for
improvement except the conceptual one described above. In the Methods section, the extraction of data
for this study is not fully explained - how many experts extracted the data, how were different terms in the
statements on writing assistance interpreted and categorized, etc.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
No
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Dissemination bias, publication integrity
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 11 Sep 2017
, PAREXEL, USAIra Mills
We thank   for her insight and providing suggestions to improve our paper.Ana Marušić
We feel that the data described herein fulfill the criteria for publication as a “Research Note” in
F1000 Research, designed to report “single-finding papers that can be reported with one or two
illustrations.” Our intention was to conduct a post hoc analysis to specifically examine the role of
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 F1000 Research, designed to report “single-finding papers that can be reported with one or two
illustrations.” Our intention was to conduct a post hoc analysis to specifically examine the role of
professional medical writing support on CONSORT adherence as previously described by two of
the authors.
In the discussion, we acknowledge that there was substantial risk of false positives given that
separate confidence intervals were computed for 19 different CONSORT items. However, the p
value for setting (item 4) was 0.0010, for harms or side effects (item 16) was 0.0004, and for
source of funding (item 19) was 0.0055; the first two survive a Bonferroni correction, which would
conservatively demand that p<0.0026, and all three pass the less stringent Benjamini-Hochberg
procedure.
We now include a note in the discussion that the limited number of articles with acknowledged
professional medical writing support did not allow further exploration of the results (e.g. type of
funding, trial phase, institutions where performed) and also mention that it would be of interest to
examine whether similar trends are observed in separate studies of CONSORT for Abstracts.
As described in the original submission, one author performed the data extraction conducting a
blinded automated search per the defined terms followed by reexamining for context. We note two
articles that were excluded from the analysis by manual review and provide rationale. In one case
there was no writing assistance from anyone not listed as an author and in the second case the
“Writing committee drafted the report…without editorial assistance.” We have made it clear that
this was performed using the full text articles. 
 No competing interests were disclosed.Competing Interests:
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